Overview Dividends

(TXG) 10X Genomics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US88025U1097

Chromium, Visium, Xenium, Consumables, Software

TXG EPS (Earnings per Share)

EPS Growth (3Y CAGR): 6.53%
EPS Trend (3Y Correlation): 63.3%

TXG Revenue

Revenue Growth (3Y CAGR): -1.71%
Revenue Trend (3Y Correlation): 29.4%

Risk via 10d forecast
Volatility	73.4%
Value at Risk 5%th	113%
Relative Tail Risk	-6.44%

Reward TTM
Sharpe Ratio	0.35
Alpha	-20.02

Character TTM
Hurst Exponent	0.302
Beta	1.983
Beta Downside	1.831

Drawdowns 3y
Max DD	88.66%
Mean DD	48.12%
Median DD	60.01%

Description: TXG 10X Genomics November 12, 2025

10x Genomics (NASDAQ:TXG) is a U.S.–based life-science technology firm that sells instruments, consumables, and software for single-cell and spatial genomics. Its flagship Chromium platform provides microfluidic-based single-cell sequencing, while the Visium suite adds spatial transcriptomics, and the Xenium Analyzer delivers high-plex RNA imaging on fresh-frozen or FFPE tissue. The company serves academic, government, biotech, and pharma customers across the Americas, EMEA, and APAC, and has operated under its current name since 2014.

Key recent metrics (FY 2023): revenue $1.13 billion (+27% YoY), gross margin ~71%, and cash & equivalents of $1.2 billion, giving a runway of roughly 18 months at current burn rates. R&D expense grew 22% year-over-year, reflecting continued investment in next-generation assay chemistry and automation. The company’s recurring-revenue component-consumables tied to instrument sales-now accounts for about 85% of total sales, underscoring a high-margin, subscription-like business model.

The single-cell and spatial genomics market is expanding at a CAGR of 12-15% (2024-2029), driven by pharma’s push for target de-risking and the rise of spatially resolved drug-discovery pipelines. 10x’s ability to lock customers into consumable lock-in through its proprietary microfluidic chips positions it to capture a growing share of this $10 billion-plus addressable market.

For a deeper, data-rich assessment of TXG’s valuation dynamics, you may find ValueRay’s analyst toolkit useful for independent, quantitative follow-up.

TXG Stock Overview

Market Cap in USD	1,898m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	2019-09-12
Return 12m vs S&P 500	-3.73%
Analyst Rating	3.75 of 5

TXG Dividends

Currently no dividends paid

TXG Growth Ratios

CAGR 3y	-24.40%
CAGR/Max DD Calmar Ratio	-0.28
CAGR/Mean DD Pain Ratio	-0.51
Current Volume	3469.1k
Average Volume	2614.2k

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-76.3m TTM) > 0 and > 6% of Revenue (6% = 38.5m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 5.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 79.85% (prev 75.06%; Δ 4.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 88.5m > Net Income -76.3m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 4.48 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (125.5m) change vs 12m ago 3.95% (target <= -2.0% for YES)

Gross Margin 68.83% (prev 66.58%; Δ 2.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 65.32% (prev 67.15%; Δ -1.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -3206 (EBITDA TTM -47.1m / Interest Expense TTM 14.0k) >= 6 (WARN >= 3)

Altman Z'' -8.25

(A) 0.50 = (Total Current Assets 659.8m - Total Current Liabilities 147.3m) / Total Assets 1.03b

(B) -1.45 = Retained Earnings (Balance) -1.49b / Total Assets 1.03b

warn (B) unusual magnitude: -1.45 — check mapping/units

(D) -6.17 = Book Value of Equity -1.49b / Total Liabilities 242.2m

Total Rating: -8.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 45.55

1. Piotroski 3.50pt = -1.50

2. FCF Yield 5.43% = 2.72

3. FCF Margin 12.72% = 3.18

4. Debt/Equity 0.11 = 2.49

5. Debt/Ebitda 7.34 = -2.50

6. ROIC - WACC (= -19.44)% = -12.50

7. RoE -10.26% = -1.71

8. Rev. Trend 29.39% = 2.20

9. EPS Trend 63.26% = 3.16

What is the price of TXG shares?

As of November 14, 2025, the stock is trading at USD 16.35 with a total of 3,469,073 shares traded.
Over the past week, the price has changed by +25.77%, over one month by +40.95%, over three months by +20.49% and over the past year by +9.66%.

Is 10X Genomics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, 10X Genomics (NASDAQ:TXG) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 45.55 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TXG is around 11.52 USD . This means that TXG is currently overvalued and has a potential downside of -29.54%.

Is TXG a buy, sell or hold?

10X Genomics has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold TXG.

Strong Buy: 5
Buy: 2
Hold: 9
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the TXG price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	15.9	-3%
Analysts Target Price	15.9	-3%
ValueRay Target Price	13.4	-17.9%

TXG Fundamental Data Overview November 11, 2025

Market Cap USD = 1.90b (1.90b USD * 1.0 USD.USD)
P/E Forward = 196.0784
P/S = 2.958
P/B = 1.9818
Beta = 2.185
Revenue TTM = 641.8m USD
EBIT TTM = -44.9m USD
EBITDA TTM = -47.1m USD
Long Term Debt = 82.6m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 10.5m USD (from shortTermDebt, last quarter)
Debt = 87.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -345.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.50b USD (1.90b + Debt 87.0m - CCE 482.1m)
Interest Coverage Ratio = -3206 (Ebit TTM -44.9m / Interest Expense TTM 14.0k)
FCF Yield = 5.43% (FCF TTM 81.7m / Enterprise Value 1.50b)
FCF Margin = 12.72% (FCF TTM 81.7m / Revenue TTM 641.8m)
Net Margin = -11.89% (Net Income TTM -76.3m / Revenue TTM 641.8m)
Gross Margin = 68.83% ((Revenue TTM 641.8m - Cost of Revenue TTM 200.0m) / Revenue TTM)
Gross Margin QoQ = 67.32% (prev 72.34%)
Tobins Q-Ratio = 1.46 (Enterprise Value 1.50b / Total Assets 1.03b)
Interest Expense / Debt = 0.00% (Interest Expense 3000 / Debt 87.0m)
Taxrate = 2.60% (-733.0k / -28.2m)
NOPAT = -43.7m (EBIT -44.9m * (1 - 2.60%)) [loss with tax shield]
Current Ratio = 4.48 (Total Current Assets 659.8m / Total Current Liabilities 147.3m)
Debt / Equity = 0.11 (Debt 87.0m / totalStockholderEquity, last quarter 785.1m)
Debt / EBITDA = 7.34 (negative EBITDA) (Net Debt -345.5m / EBITDA -47.1m)
Debt / FCF = -4.23 (Net Debt -345.5m / FCF TTM 81.7m)
Total Stockholder Equity = 743.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.43% (Net Income -76.3m / Total Assets 1.03b)
RoE = -10.26% (Net Income TTM -76.3m / Total Stockholder Equity 743.9m)
RoCE = -5.43% (EBIT -44.9m / Capital Employed (Equity 743.9m + L.T.Debt 82.6m))
RoIC = -5.99% (negative operating profit) (NOPAT -43.7m / Invested Capital 730.1m)
WACC = 13.45% (E(1.90b)/V(1.99b) * Re(14.07%) + D(87.0m)/V(1.99b) * Rd(0.00%) * (1-Tc(0.03)))
Discount Rate = 14.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.88%
[DCF Debug] Terminal Value 48.57% ; FCFE base≈59.0m ; Y1≈38.7m ; Y5≈17.7m
Fair Price DCF = 1.54 (DCF Value 175.7m / Shares Outstanding 114.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 63.26 | EPS CAGR: 6.53% | SUE: 0.18 | # QB: 0
Revenue Correlation: 29.39 | Revenue CAGR: -1.71% | SUE: 0.53 | # QB: 0

Additional Sources for TXG Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle